S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
One company did the impossible with AI (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
One company did the impossible with AI (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
HUGE BUY ALERT: Move Fast, Musk… (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
One company did the impossible with AI (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
One company did the impossible with AI (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
HUGE BUY ALERT: Move Fast, Musk… (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
One company did the impossible with AI (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
One company did the impossible with AI (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
HUGE BUY ALERT: Move Fast, Musk… (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
One company did the impossible with AI (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
One company did the impossible with AI (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
HUGE BUY ALERT: Move Fast, Musk… (Ad)
What to watch for as China's major political meeting of the year gets underway
NASDAQ:PCRX

Pacira BioSciences (PCRX) Stock Price, News & Analysis

$28.86
-0.86 (-2.89%)
(As of 03/1/2024 ET)
Today's Range
$28.68
$30.01
50-Day Range
$27.70
$35.48
52-Week Range
$25.93
$48.60
Volume
662,217 shs
Average Volume
540,801 shs
Market Capitalization
$1.34 billion
P/E Ratio
35.63
Dividend Yield
N/A
Price Target
$50.00

Pacira BioSciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
73.3% Upside
$50.00 Price Target
Short Interest
Bearish
8.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.89
Upright™ Environmental Score
News Sentiment
0.12mentions of Pacira BioSciences in the last 14 days
Based on 26 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
17.05%
From $2.64 to $3.09 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.62 out of 5 stars

Medical Sector

87th out of 950 stocks

Pharmaceutical Preparations Industry

30th out of 428 stocks


PCRX stock logo

About Pacira BioSciences Stock (NASDAQ:PCRX)

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

PCRX Stock Price History

PCRX Stock News Headlines

Navigating 4 Analyst Ratings For Pacira BioSciences
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Q4 2023 Pacira Biosciences Inc Earnings Call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Preview: Pacira BioSciences's Earnings
Pacira BioSciences Q4 2023 Earnings Preview
PCRX Mar 2024 32.500 put
PCRX Mar 2024 40.000 call
PCRX May 2024 42.500 call
See More Headlines
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/02/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
715
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$50.00
High Stock Price Target
$57.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+73.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$15.91 million
Pretax Margin
9.14%

Debt

Sales & Book Value

Annual Sales
$665.69 million
Cash Flow
$3.38 per share
Book Value
$18.74 per share

Miscellaneous

Free Float
43,373,000
Market Cap
$1.34 billion
Optionable
Optionable
Beta
0.76
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report














PCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings
or view top-rated stocks.

What is Pacira BioSciences' stock price target for 2024?

9 equities research analysts have issued 12 month price targets for Pacira BioSciences' shares. Their PCRX share price targets range from $42.00 to $57.00. On average, they anticipate the company's stock price to reach $50.00 in the next year. This suggests a possible upside of 73.3% from the stock's current price.
View analysts price targets for PCRX
or view top-rated stocks among Wall Street analysts.

How have PCRX shares performed in 2024?

Pacira BioSciences' stock was trading at $33.74 at the beginning of 2024. Since then, PCRX shares have decreased by 14.5% and is now trading at $28.86.
View the best growth stocks for 2024 here
.

When is Pacira BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our PCRX earnings forecast
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its quarterly earnings results on Tuesday, November, 2nd. The company reported $0.72 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.07. The business had revenue of $127.70 million for the quarter, compared to analyst estimates of $129.69 million. Pacira BioSciences had a trailing twelve-month return on equity of 12.81% and a net margin of 6.22%. The company's quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.43 earnings per share.

What ETFs hold Pacira BioSciences' stock?
What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $680.0 million-$705.0 million, compared to the consensus revenue estimate of $722.5 million.

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.98%), Frontier Capital Management Co. LLC (4.49%), Dimensional Fund Advisors LP (3.04%), Stephens Investment Management Group LLC (2.84%), Vestal Point Capital LP (2.58%) and Clearbridge Investments LLC (2.47%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends
.

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PCRX) was last updated on 3/3/2024 by MarketBeat.com Staff